EDAP TMS Reports Continued Progress in European Marketing
12 July 2005 - 11:00PM
PR Newswire (US)
EDAP TMS Reports Continued Progress in European Marketing LYON,
France, July 12 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP) is pleased to report continued growing interest in
minimally invasive prostate cancer treatment utilizing the
company's market leading Ablatherm(R)-HIFU platform at two
conferences held in Europe. EDAP participated in the 6th
International Consultation on New Developments in Prostate Cancer
and Prostate Diseases, co-sponsored by the International Union
Against Cancer, in Paris, June 24-27, 2005. The conference is the
most recognized worldwide event for discussing prostate cancer and
prostate disease while assessing new trends in the fast developing
area of research against cancer. Pr. Pierre Conort, from Hopital La
Pitie Salpetriere in Paris, presented an overview of features
unique to Ablatherm(R)-HIFU including safety, quality ultrasound
imaging, long-term clinical data, reduced occurrence of side
effects and repeatability of treatment while discussing key factors
differentiating Ablatherm-HIFU from other technology. Pr. Conort
has used Ablatherm-HIFU to successfully treat localized prostate
cancer for more than four years. Pr. Pierre Conort commented:
"Ablatherm-HIFU is the only proven technology based on long-term
clinical data. It has been used on a routine basis, for
well-selected patients whose treatment requires its unique
benefits, since 2001. Ablatherm-HIFU treatment has a multi-year
body of clinical data demonstrating very low side effects and high
tolerance in patients. Additionally, it is a valuable option for
patients who failed a prior radiotherapy procedure and do not have
other alternatives for their prostate cancer treatment." The
Ablatherm-HIFU unit recently introduced an industry leading
enhanced 3-D integrated imaging system allowing the urologist to
efficiently visualize the patient prostate while focusing the high
intensity ultrasound. Using the optimized parameters developed
based on years of clinical practice, urologists can safely and
effectively treat localized prostate cancer. The continuous
refinement of these parameters has steadily reduced the incidence
of typical side effects reported in other traditional treatments
while offering the patient an easier recovery as compared to
surgical removal of the diseased prostate. Dr. John Warner, from
the Don Mills Surgical Unit in Toronto, Canada, presented a video
session on Ablatherm-HIFU detailing an Ablatherm treatment
procedure and discussing the various steps. Dr. Warner also
discussed how the newly integrated imaging system enhances detail
in imaging and control for the physician during treatment. He
concluded by presenting Ablatherm-HIFU five-year results and
successful outcomes for radiotherapy failure patients. This
presentation was highly attended and urologists demonstrated great
interest in inquiring further about this technique and its unique
advantages. EDAP also presented at the B.A.U.S. (British
Association of Urology Surgeons) meeting held in Glasgow, Scotland,
from June 27 to July 1, 2005. Ablatherm-HIFU received approval from
the National Institute for Clinical Excellence (NICE) in early
2005, a key recommendation for acceptance within the U.K. urology
community as well as future insurance reimbursement of the
procedure. British Urologists showed great interest specifically in
Ablatherm-HIFU technology as an additional treatment option for
patients who are ill equipped to handle the rigors of surgery or
who failed previous radiation treatment. Urologists visited with
representatives from both EDAP and its U.K. distributor Sigmacon to
discuss Ablatherm-HIFU treatment of prostate cancer as well as take
part in informational discussions about the technology and its
results. "We are very pleased with the outcomes from these two
conference events in furthering the demand for and recognition of
Ablatherm-HIFU as the leading minimally invasive therapeutic option
for the treatment of localized prostate cancer in Europe," said
Hugues de Bantel, CEO of EDAP. "EDAP will continue to build on its
strength in clinical results as we successfully treat an ever
increasing number of patients seeking an alternative to traditional
therapies for localized prostate cancer." Commenting on the
company's continued growth in the U.K. market, de Bantel stated,
"We are very pleased to begin active work in the U.K. to advance
the knowledge of this very attractive treatment option within the
urology community. The pipeline is building for the U.K. market as
we continue in our efforts to gain reimbursement approval." About
EDAP TMS S.A. EDAP TMS S.A. develops and markets Ablatherm, the
most advanced and clinically proven choice for High Intensity
Focused Ultrasound (HIFU) treatment of localized prostate cancer.
HIFU treatment is shown to be a minimally invasive and effective
treatment option with a low occurrence of side effects. The company
is also developing this technology for the treatment of certain
other types of tumors. EDAP TMS S.A. also produces and
commercializes medical equipment for treatment of urinary tract
stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more
information on the Company, contact the Investor Relations Dept by
phone at +33 (0) 4 78 26 40 46 or see the Company's Web site at:
http://www.edap-tms.com/ . This press release contains, in addition
to historical information, forward-looking statements that involve
risks and uncertainties. These include statements regarding the
Company's growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. CONTACT: EDAP TMS S.A. Hugues
de Bantel - Philippe Chauveau Blandine Confort +33 4 78 26 40 46
Halliburton Investor Relations Matt Kreps - Geralyn DeBusk 972 458
8000 DATASOURCE: EDAP TMS S.A. CONTACT: Hugues de Bantel, Philippe
Chauveau, or Blandine Confort, all of EDAP TMS S.A.,
+33-4-78-26-40-46; or Matt Kreps, or Geralyn DeBusk, both of
Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A.
Web site: http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024